Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00453180Phase 2Completed

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

Role: collaborator

NCT00319722Unknown

EEG Studies of Sensory Processing in Autistic Children

Role: collaborator

NCT00252603Phase 3Completed

Galantamine Versus Placebo in Childhood Autism

Role: collaborator

All 3 trials loaded